Comparing two targeted therapies before surgery for HER2-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial compares two drugs, trastuzumab rezetecan and trastuzumab deruxtecan, given before surgery to shrink HER2-positive breast cancer tumors. It aims to see which drug works better and has fewer side effects, potentially offering a more effective treatment option for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 to 75 years, and you have not received any previous treatment for breast cancer.
- Your breast cancer is HER2-positive and either early-stage or locally advanced, and it has not spread to distant organs.
- You are in good general health, able to perform daily activities, and your heart, liver, and kidney functions are within normal limits.
- You have not had chemotherapy, radiation, or targeted therapy before, and you have not had other cancers in the past 5 years (except cured skin or cervical cancer).
- You are not pregnant and you agree to use effective contraception during the trial.
- You are willing to sign a consent form and follow the trial procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted therapies given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach is safe and effective for early-stage breast cancer.
This Phase 2 study compares trastuzumab deruxtecan to standard chemotherapy given before surgery for HER2-positive breast cancer. It aims to see which treatment works better to shrink the tumor and spread before the operation.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This trial compares two combinations of drugs given before surgery to shrink HER2-positive breast cancer. One uses a new experimental drug (TQB2102) and the other uses standard treatments. The goal is to see which works better at reducing the cancer before surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.